Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

por Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publicado 2021

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)

por Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, Takao Kobayashi, Hideaki Maeda, Mashio Nakamura, Norifumi Nakanishi, Norikazu Yamada, Tsubasa Tajima, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki
Publicado 2021